Bioheart Extends Licenses of Electrical Stimulation Patents With Airspeed

Wed Oct 17, 2012 7:12am EDT

* Reuters is not responsible for the content in this press release.

  SUNRISE, FL, Oct 17 (Marketwire) -- 
Bioheart, Inc. (OTCQB: BHRT) today announced that they have agreed to
extend the license agreement with Airspeed for four separate Bioheart
patents. The patents include methods of electrical stimulation and
biological pacing, which are marketed under the MyoStim(TM) product line.
Airspeed holds exclusive rights to these patents and all products
associated with the patents and pays Bioheart milestone payments and
royalties based on future sales of products. MyoStim is pursuing initial
safety and efficacy trials in both wound care and heart failure using the
Wound Healing and Regeneration Accelerator units (MWHA-1).

    Mike Tomas, President and CEO, said, "Bioheart is currently focused on
our core assets for heart failure patients and is enthusiastic about
Airspeeds ability to bring Bioheart's electrical stimulation technologies
to market."

    Alan Remen, Airspeed Holdings' Managing Director and MyoStim's Co-Founder
and CEO, said, "This technology may help to stimulate the body's own
bio-electric 'homing' signal to recruit stem cells to the site of injury
and grow new blood vessels, which can be an effective therapy for
critical wounds and heart failure." 

    About Bioheart, Inc.

    Bioheart is committed to maintaining its leading position within the
cardiovascular sector of the cell technology industry delivering cell
therapies and biologics that help address congestive heart failure, lower
limb ischemia, chronic heart ischemia, acute myocardial infarctions and
other issues. Bioheart's goals are to cause damaged tissue to be
regenerated, when possible, and to improve a patient's quality of life
and reduce health care costs and hospitalizations. 

    Specific to biotechnology, Bioheart is focused on the discovery,
development and, subject to regulatory approval, commercialization of
autologous cell therapies for the treatment of chronic and acute heart
damage and peripheral vascular disease. Its leading product, MyoCell, is
a clinical muscle-derived cell therapy designed to populate regions of
scar tissue within a patient's heart with new living cells for the
purpose of improving cardiac function in chronic heart failure patients.
For more information on Bioheart, visit, or visit us
on Facebook: Bioheart and Twitter @BioheartInc. 

    About Airspeed Holdings, LLC

    Headquartered in San Diego, Airspeed is a private investment,
entrepreneurial capital management firm and leading edge, multi-project
business development enterprise that creates and nurtures new technology

    Forward-Looking Statements: Except for historical matters contained
herein, statements made in this press release are forward-looking
statements. Without limiting the generality of the foregoing, words such
as "may," "will," "to," "plan," "expect," "believe," "anticipate,"
"intend," "could," "would," "estimate," or "continue" or the negative
other variations thereof or comparable terminology are intended to
identify forward-looking statements.

    Forward-looking statements involve known and unknown risks, uncertainties
and other factors which may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Also, forward-looking statements represent our management's
beliefs and assumptions only as of the date hereof. Except as required by
law, we assume no obligation to update these forward-looking statements
publicly, or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, even if new
information becomes available in the future.

    The Company is subject to the risks and uncertainties described in its
filings with the Securities and Exchange Commission, including the
section entitled "Risk Factors" in its Annual Report on Form 10-K for the
year ended December 31, 2011, and its Quarterly Report on Form 10-Q for
the quarter ended March 31, 2012.


Media Contact: 
Rhonda Madaris
13794 NW4th Street
Suite 212
Sunrise, FL 33325
Telephone 954/835-1500

Copyright 2012, Marketwire, All rights reserved.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.